In federal law, misbranding means a product’s label is false or misleading, or is missing information the law requires it to carry. The Federal Food, Drug, and Cosmetic Act (FDCA) applies this standard to food, drugs, medical devices, and cosmetics, and shipping a misbranded product across state lines is a federal crime. Fines can reach $250,000 for an individual and $500,000 for an organization, and the FDA can seize noncompliant goods and shut down distribution through a court order.
What Makes a Product Misbranded
The FDCA makes it illegal to introduce a misbranded product into interstate commerce, to misbrand a product while it is in interstate commerce, or to receive a misbranded product and resell it.1Office of the Law Revision Counsel. 21 USC 331 – Prohibited Acts Each product category has its own detailed misbranding statute, but four triggers repeat across all of them.
The first is false or misleading labeling. If any statement on the label is untrue or creates a misleading impression, the product is misbranded. This is the broadest trigger. The statute uses the phrase “in any particular,” meaning a single misleading detail is enough.2Office of the Law Revision Counsel. 21 USC 343 – Misbranded Food
The second is a misleading container. Packaging shaped or filled in a way that leads a consumer to believe there is more product inside than actually exists violates the law. A box filled to half its height with no structural reason for the extra space is a textbook example.
The third is missing required information. Every label must include specific details, such as the manufacturer’s name and address and the net quantity of contents. Leaving any of them off makes the product misbranded automatically.
The fourth is information that is technically present but hard to read. Even if the right information appears on the label, the product is misbranded if the text is not prominent enough for an ordinary consumer to find and read under normal shopping conditions.3FDA. Cosmetics Labeling Guide
Misbranding vs. Adulteration
Misbranding is often confused with adulteration, the other major violation under the FDCA. Adulteration deals with what is physically wrong with a product: contamination, unsafe ingredients, or substandard manufacturing conditions. Misbranding is about how the product is presented. A food can be perfectly safe to eat and still be misbranded because its label omits an allergen declaration or overstates its nutritional value. The two violations can and often do apply to the same product at the same time.
How the Rules Change by Product Type
Food
Packaged food carries some of the most detailed requirements in federal law. Under 21 U.S.C. § 343, a label must show the common name of the food, the manufacturer’s name and address, an accurate net quantity, an ingredient list in descending order by weight, a nutrition facts panel, and any required allergen declarations.2Office of the Law Revision Counsel. 21 USC 343 – Misbranded Food A food sold under the name of a different food, or one that imitates another food without saying “imitation” on the label, is also misbranded. Nutrient content claims like “low fat” or “high fiber” are misbranding violations if the product does not meet the specific thresholds the FDA has defined for each term.4eCFR. 21 CFR Part 101 – Food Labeling
Undeclared allergens are one of the most common enforcement triggers. Federal law recognizes nine major food allergens: milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame. Sesame was added by the FASTER Act, with mandatory labeling effective January 1, 2023.5FDA. The FASTER Act: Sesame Is the Ninth Major Food Allergen Any product containing one of these allergens or an ingredient derived from one must declare it, either in the ingredient list or in a separate “Contains” statement.
Foods that are bioengineered fall under a separate USDA-administered disclosure standard rather than the FDA’s rules. Manufacturers can disclose on-package, through a USDA-approved symbol, a QR code, or a text-message number, and knowingly failing to disclose is a prohibited act.6Office of the Law Revision Counsel. 7 USC 1639b – National Bioengineered Food Disclosure Standard
Drugs and Medical Devices
Drugs and devices are governed by 21 U.S.C. § 352.7Office of the Law Revision Counsel. 21 USC 352 – Misbranded Drugs and Devices The false-or-misleading baseline applies, and drug labels must also provide adequate directions for use, meaning indications, dosage, frequency, duration, route of administration, and any relevant warnings or side effects.8eCFR. 21 CFR Part 201 – Labeling A label that omits warnings about use in children, use with certain conditions, or interactions with other drugs makes the product illegal to sell. Medical devices carry an additional Unique Device Identification requirement, with the identifier appearing in both plain text and machine-readable form.9FDA. UDI Basics
Cosmetics
Cosmetics fall under 21 U.S.C. § 362. A cosmetic in package form must show the name and place of business of the manufacturer, packer, or distributor, along with an accurate net quantity.10Office of the Law Revision Counsel. 21 USC 362 – Misbranded Cosmetics The same prominence and misleading-container rules apply, and ingredients must be listed under the FDA’s cosmetic labeling regulations.11eCFR. 21 CFR Part 701 – Cosmetic Labeling A frequent trap: cosmetics that make drug-like claims. A moisturizer that says “reduces wrinkles” is a cosmetic; one that says “treats eczema” has crossed into drug territory and must meet the more demanding drug labeling rules, or face misbranding charges under both statutes.
Dietary Supplements
Supplements sit between food and drugs. Under the Dietary Supplement Health and Education Act of 1994, manufacturers are responsible for evaluating safety and labeling before marketing, and the FDA can act against a supplement that turns out to be misbranded after it reaches the market.12FDA. Dietary Supplements Supplement labels may carry “structure/function” claims like “calcium builds strong bones,” but each such claim must appear alongside a specific disclaimer, displayed prominently and in boldface: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.” Burying the disclaimer or leaving it off makes the product misbranded. Claims that cross into diagnosing, treating, or preventing a specific disease are prohibited entirely and can reclassify the supplement as an unapproved drug.
Penalties
Criminal penalties operate on two levels under 21 U.S.C. § 333. The base misdemeanor carries up to one year in prison.13Office of the Law Revision Counsel. 21 USC 333 – Penalties The misbranding statute itself lists a fine of $1,000 for the base offense, but a separate federal sentencing law lets courts impose up to $100,000 on an individual convicted of a misdemeanor and $200,000 on an organization.14Office of the Law Revision Counsel. 18 USC 3571 – Sentence of Fine
Penalties escalate sharply in two situations: when the violator has a prior FDCA conviction, or when the violation was committed with intent to defraud or mislead. The maximum prison sentence rises to three years, and the fine ceiling rises to $250,000 for individuals and $500,000 for organizations.
The government can also seize the goods themselves. Any misbranded food, drug, or cosmetic in interstate commerce, or held for sale after interstate shipment, is subject to court-ordered seizure.15Office of the Law Revision Counsel. 21 USC 334 – Seizure Federal officials pull the products from shelves or warehouses, and seized goods are typically destroyed or relabeled under court supervision.
How the FDA Enforces the Rules
Enforcement usually starts with a letter, not a lawsuit. A warning letter addresses a significant violation, states that failure to correct could lead to enforcement action, and is published on the FDA’s website. Trade press routinely picks these up, which can affect stock prices, business relationships, and future FDA interactions.16FDA. Letters to Industry An untitled letter addresses violations below that threshold, requests correction without threatening enforcement, and may never be made public.17FDA. Issuance of Untitled Letters The FDA has no legal obligation to send either before taking formal action. A warning letter typically requests a written corrective action plan within 15 working days.
When voluntary compliance fails, the FDA can ask a federal court for an injunction under 21 U.S.C. § 332 ordering the company to stop distributing the misbranded products.18Office of the Law Revision Counsel. 21 USC 332 – Injunction Proceedings These orders often include third-party audits, mandatory testing, and ongoing FDA oversight of labeling decisions. Violating the order adds contempt charges to the original violations.
Recalls are another common response. Most are technically voluntary, initiated by the manufacturer, but the FDA monitors the process and can mandate a recall for certain product categories if the company refuses to act.19FDA. Recalls Background and Definitions The agency classifies recalls by health risk, from Class I (reasonable probability of serious harm or death) through Class III (unlikely to cause any adverse health effects).
Foreign manufacturers face import detention. When the FDA finds imported products in violation, it can place the product or manufacturer on an import alert list, and future shipments are held automatically at the border until the importer demonstrates compliance. For a misbranding violation, an importer may resolve a detention by submitting a relabeling proposal and showing the corrected labels meet all requirements before the goods enter U.S. commerce.